Home 
Sitemap
Contact Us
| Cellceutix of Wilmington Mass completed a $400,000 9 percent secured convertible debenture finan |
|
Cellceutix, of Wilmington, Mass., completed a $400,000 9 percent secured convertible debenture financing. Proceeds will be used to advance the development of Kevetrin, the company's lead drug candidate in head and neck cancers. Under the terms, the debentures and concomitant interest are due Dec. 1, 2009, and are convertible into the company's common stock at $1.50 per share. Cellceutix's stock (OTC BB:CTIX) remained unchanged Wednesday at 80 cents. By Jennifer Boggs Assistant Managing Editor Original story can be found here. |
